EKLF Gene Expression in β-thalassemia

Launched by ROFAIDA HASSAN AHMED · May 31, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "EKLF Gene Expression in β-thalassemia," is looking to understand how the EKLF gene behaves in patients with β-thalassemia, a blood disorder that affects how the body produces hemoglobin. The researchers want to find out if there is a link between the way this gene is expressed and the symptoms that patients experience. This study is not yet recruiting participants, but it will include both men and women aged 18 to 29 who have been diagnosed with either major or intermedia β-thalassemia. However, individuals with other types of hemolytic anemia will not be eligible to participate.

If you or someone you know has β-thalassemia and is within the specified age range, you might be eligible to join this study when it begins. Participants will have the opportunity to contribute to important research that could help improve understanding and treatment options for this condition. While specific details about what participants can expect during the trial are not mentioned yet, being part of such a study can provide valuable insights into the disease and its management.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with β-thalassemia (major and intermedia).
• • patients are of both sexes (male or female) at any age
• Exclusion Criteria:
• • patients with any other types of hemolytic anaemia